NVDA
NVIDIA
-- 133.970 TSLA
Tesla
-- 466.700 QUBT
Quantum Computing
-- 24.552 RGTI
Rigetti Computing
-- 10.7588 MU
Micron Technology
-- 107.830 
Biotech Company Announces Positive Data Results For Alopecia Treatment
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata.
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, recently announced promising topline results from its Phase 2 proof-of-concept (PoC) study of EQ101 in adult patients suffering from moderate, severe, or very-severe alopecia areata (AA). This autoimmune condition, driven by an immune cell attack on hair follicles, leads to significant hair loss. $Equillium (EQ.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment